International Clinical Trial: A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855276) titled 'A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Novartis Pharmaceuticals

Condition: Hidradenitis Suppurativa

Intervention: Drug: LOU064

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 14, 2026

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/study/NCT07855276

Published by HT Digital Content S...